TREATMENT.COM AI INC.

UNAUDITED CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2024

(Expressed in Canadian dollars)

TREATMENT.COM AI INC.
UNAUDITED CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
AS OF SEPTEMBER 30, 2024 AND DECEMBER 31, 2023
(Expressed in Canadian Dollars)

	September 30, 2024	December 31, 2023
	$	$
ASSETS		
Current assets		
Cash	230,700	715,529
Amounts receivable	-	17,247
Prepaid expenses	652,576	6,530
TOTAL ASSETS	883,276	739,306
LIABILITIES		
Current liabilities		
Accounts payable and accrued liabilities (Note 11)	433,240	892,573
Convertible debenture (Note 5)	-	442,135
Loan payable (Note 6)	127,165	142,651
TOTAL LIABILITIES	560,405	1,477,359
SHAREHOLDERS' EQUITY (DEFICIENCY)		
Share capital (Note 7)	23,922,012	19,069,847
Reserve (Note 7)	9,234,517	7,819,953
Accumulated other comprehensive loss	(110,162)	(101,169)
Deficit	(32,723,496)	(27,526,684)
TOTAL SHAREHOLDERS’ EQUITY (DEFICIENCY)	322,871	(738,053)
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY (DEFICIENCY)	883,276	739,306

Note 1: Nature of business and continuing operations
Note 12: Contingencies
Note 14: Subsequent events

Approved and authorized by the Board on November 26, 2024:

“Essam Hamza”
Essam Hamza, Director

“Kevin Peterson”
Kevin Peterson, Director

The accompanying notes are an integral part of these unaudited condensed interim consolidated financial statements

TREATMENT.COM AI INC.
UNAUDITED CONDENSED INTERIM CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2024 AND 2023
(Expressed in Canadian Dollars)

	Three Months Ended September 30, 2024	**Three Months Ended September 30, 2023 (Restated – Note 13)**	**Nine Months Ended September 30, 2024**	**Nine Months Ended September 30, 2023 (Restated – Note 13)**
	$	$	$	$
Revenues	10,990	-	10,990	-
Expenses				
Accretion and financing fees (Note 5)	-	19,075	33,360	56,643
Consulting and professional fees (Note 11)	568,104	466,527	1,844,190	871,476
General and administration	463,704	30,402	733,776	111,120
Research	-	300,000	27,100	300,000
Salaries & benefits (Note 11)	234,221	-	457,139	3,653
Stock-based compensation (Note 7)	(102,957)	59,157	730,827	201,567
Total expenses	1,163,072	875,161	3,826,392	1,544,459
Loss from operations	(1,152,082)	(875,161)	(3,815,402)	(1,544,459)
Other income	-	38,136	-	38,136
Foreign exchange loss	(9,762)	(304)	(17,489)	(557)
Write-off of accounts payable (Note 7)	-	26,762	-	26,762
Loss on settlement of payables for equity (Note 7)	(499,106)	(1,500,009)	(499,106)	(1,500,009)
Loss on restructuring of convertible debt (Note 7)	-	-	(971,435)	-
Loss for the period	(1,660,950)	(2,310,576)	(5,303,432)	(2,980,127)
Foreign exchange translation	(1,303)	(8,939)	(8,993)	(332)
Comprehensive loss for the period	(1,662,253)	(2,319,515)	(5,312,425)	(2,980,459)
Loss per share – basic and diluted	(0.03)	(0.33)	(0.13)	(0.22)
Weighted average number of outstanding common shares, basic and diluted	48,006,452	6,934,374	41,737,561	13,762,787

TREATMENT.COM AI INC.
UNAUDITED CONDENSED INTERIM CONSOLIDATED STATEMENTS OF SHAREHOLDERS' DEFICIENCY
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2024 AND 2023
(Expressed in Canadian Dollars)

	Number of Preferred Shares	Number of Common Shares	Share Capital $	Subscriptions Received In Advance $	Reserve $	Accumulated Other Comprehensive Loss $	Deficit $	Total $
Balance, December 31, 2022	10,001	6,624,399	14,508,513	-	7,208,230	(101,044)	(23,804,302)	(2,188,603)
Shares issued to settle debts for services	-	18,005,716	3,303,511	-	-	-	-	3,303,511
Shares issued to private Placement		10,000,000	1,000,000	-	-	-	-	1,000,000
Share issuance cost	-	-	(49,914)	-	32,414	-	-	(17,500)
Subscriptions received in Advance	-	-	-	15,000	-	-	-	15,000
Stock-based compensation	-	-	-	-	201,567	-	-	201,567
Other comprehensive income	-	-	-	-	-	(332)	-	(332)
Loss for the period	-	-	-	-	-	-	(2,980,127)	(2,980,127)
Balance, September 30, 2023	10,001	34,630,115	18,762,110	15,000	7,442,211	(101,376)	(26,784,429)	(666,484)
Balance, December 31, 2023	10,001	37,105,115	19,069,847	-	7,819,953	(101,169)	(27,526,684)	(738,053)
Shares issued to settle Payables	-	1,160,713	1,149,106	-	-	-	-	1,149,106
Shares issued to settle convertible debts	-	1,143,403	1,169,468	-	263,182	-	-	1,432,650
Shares issued for services	-	39,775	30,627	-	-	-	-	30,627
Shares issued for exercise of warrants	-	953,690	542,890	-	-	-	-	542,890
Shares issued for exercise of RSUs	-	700,000	470,000	-	(470,000)	-	-	-
Shares issued for Unit Placement	-	975,000	263,877	-	126,123	-	-	390,000
Expiration of warrants	-	-	-	-	(106,620)	-	106,620	-
Shares issued for automatic conversion of special warrants	-	6,295,500	1,703,832	-	814,368	-	-	2,518,200
Share issuance costs - cash	-	-	(284,827)	-	(136,124)	-	-	(420,951)
Share issuance costs – Warrants	-	-	(192,808)	-	192,808	-	-	-
Stock-based compensation	-	-	-	-	730,827	-	-	730,827
Other comprehensive loss	-	-	-	-	-	(8,993)	-	(8,993)
Loss for the period	-	-	-	-	-	-	(5,303,432)	(5,303,432)
Balance, September 30, 2024	10,001	48,373,196	23,922,012	-	9,234,517	(110,162)	(32,723,496)	322,871

The accompanying notes are an integral part of these unaudited condensed interim consolidated financial statements

TREATMENT.COM AI INC.
UNAUDITED CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2024 and 2023
(Expressed in Canadian Dollars)

Nine Months Ended September 30,	**2024**	**2023**
	$	$
Cash flows used in operating activities		
Loss for the period	(5,303,432)	(2,980,127)
Items not involving cash		
Accretion and financing fees	19,080	56,643
Shares issued for services	30,627	3,502
Loss on settlement of payables for equity	499,105	1,500,009
Loss on restructuring of convertible debt	971,435	-
Stock-based compensation	730,827	201,567
Changes in non-cash working capital items:		
- Receivable	27,247	(16,899)
- Prepaid expenses	(646,046)	(113,069)
- Accounts payable and accrued liabilities	190,668	1,259,853
Cash used in operating activities	(3,480,489)	(88,521)
Cash flows from financing activities		
Loan payable, net of repayments	(15,486)	(13,749)
Shareholder receivable	(10,000)	-
Exercise of warrants	542,890	-
Subscriptions received in advance	-	15,000
Proceeds from private placement, net	2,487,249	982,500
Cash provided by financing activities	3,004,653	983,751
Effect of foreign exchange rate on cash	(8,993)	(332)
Net cash inflows (outflows)	(484,829)	894,898
Cash, beginning of period	715,529	2,495
Cash, end of period	230,700	897,393
Supplemental Disclosure of Non-Cash Operating, Investing, and Financing Activities		
Interest converted to common shares	57,363	-
Shares for issued for debt	1,169,468	-

The accompanying notes are an integral part of these unaudited condensed interim consolidated financial statements.

1. NATURE OF BUSINESS AND CONTINUING OPERATIONS

Treatment.com AI Inc. (the "Company" or "Treatment") was incorporated on February 2, 2018, pursuant to the provisions of the *Canada Business Corporations Act*. The Company was continued under the *Business Corporations Act* (British Columbia) on June 21, 2023. The Company's registered head office address Suite 1500, 1055 West Georgia Street, Vancouver, BC V6E 4N7.

Treatment, through its wholly owned subsidiary Treatment.com Inc. ("Treatment Inc."), is in the business of providing personalized health care information that is relevant and trustworthy empowering patients to make responsible, informed decisions about their health while improving communications, reducing costs and in-clinic wait times for medical practitioners.

The Company has been relying on equity-based financing to fund its operations. As of September 30, 2024, the Company has yet to generate a positive net income and had an accumulated deficit of $32,723,496. The Company will require additional financing either through equity or debt financing or a combination thereof to meet its administrative costs and to develop its business. There is no assurance that sufficient future funding will be available on a timely basis or on terms acceptable to the Company. These conditions indicate the existence of material uncertainties that cast significant doubt as to the ability of the Company to meet its obligations as they come due, and accordingly, the appropriateness of the use of accounting principles applicable to a going concern is in significant doubt. These unaudited condensed interim consolidated financial statements do not include any adjustments to the amounts and classification of assets and liabilities that might be necessary should the Company be unable to continue in business. Such adjustments could be material.

2. STATEMENT OF COMPLIANCE

These unaudited condensed interim consolidated financial statements are prepared by the Company in accordance with IFRS Accounting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"), in accordance with International Accounting Standards ("IAS") 34 *Interim Financial Reporting* and should be read in conjunction with the Company's annual consolidated financial statements for the year ended December 31, 2023.

The policies applied in these unaudited condensed interim consolidated financial statements are based on IFRS issued and outstanding as of November 26, 2024, the date the Board of Directors approved the statements. The same accounting policies and methods of computation are followed in these unaudited condensed interim consolidated financial statements as compared with the most recent annual consolidated financial statements as of and for the year ended December 31, 2023, except as noted below. Any subsequent changes to IFRS that are given effect in the Company's annual consolidated financial statements for the year ended December 31, 2024 could result in restatement of these unaudited condensed interim consolidated financial statements.

3. MATERIAL ACCOUNTING POLICIES

The accounting policies, critical judgements, and estimates used to prepare these condensed interim consolidated financial statements are consistent with those applied and disclosed in our consolidated financial statements for the year ended December 31, 2023.

The Company generates revenues from its artificial intelligence ("AI") platform, which provides consumer information, medical education, and clinical information support services. The Company considers IFRS 5-step revenue recognition framework when assessing appropriate revenue recognition as follows:

- Identify the contract(s) with a customer.
- Identify the performance obligations in the contract.
- Determine the transaction price.
- Allocate the transaction price to the performance obligations in the contract.
- Recognise revenue when (or as) the entity satisfies a performance obligation.

3. MATERIAL ACCOUNTING POLICIES (continued)

The Company provides services, such as scoring of medical school exams and grade reporting, to educational institutions.

The Company accounts for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable.

The Company evaluates the services promised in each contract at inception to determine whether the Company should account for the contract as having one or more performance obligations. Each of the Company's solutions is capable of being distinct as the customer can benefit from each individual solution on its own or with other resources that are readily available.

The Company performs under various types of contracts, which generally include firm-fixed-price and time-and-materials contracts. Under fixed-price contracts, the Company agrees to perform the specified work for a pre-determined price. To the extent the Company's actual costs vary from the estimates upon which the price was negotiated, the Company will generate more or less profit or could incur a loss. Under time-and-materials contracts, the Company agrees to perform the specified work for a pre-determined rate per hour, as well as the reimbursement of other direct billable costs which are presented on a gross basis.

The Company assesses each contract at its inception to determine whether it should be combined with other contracts. When making this determination, the Company considers factors such as whether two or more contracts were negotiated and executed at or near the same time or were negotiated with an overall profit objective. If combined, the Company treats the combined contracts as one single contract for revenue recognition purposes.

The Company recognizes revenue as performance obligations are satisfied and the customer obtains control of the solutions and services. In determining when performance obligations are satisfied, the Company considers factors such as contract terms, payment terms and whether there is an alternative future use of the solution or service. Substantially all of the Company's revenue to date has been recognized at a point in time because control of the performance obligation transfers to the customer at a point in time.

4. BASIS OF PRESENTATION

These unaudited condensed interim consolidated financial statements have been prepared using the historical cost basis, except those recognized at fair value and cash flow information.

The unaudited condensed interim consolidated financial statements include the accounts of Treatment Inc. and the accounts of Treatment, the subsidiary for accounting purposes.

A subsidiary is an entity in which the Company has control, where control requires exposure or rights to variable returns and the ability to affect those returns through power over the investees. All intercompany transactions and balances have been eliminated in consolidation.

5. CONVERTIBLE DEBENTURE

Activity related to the Company's convertible debenture is as follows:

(Expressed in Canadian Dollars)

5. CONVERTIBLE DEBENTURE (continued)

Balance, December 31, 2022	$	366,208
Amortization of financing costs		26,059
Accretion and interests		30,584
Balance, September 30, 2023	$	422,851
Amortization of financing costs		3,666
Accretion and interests		15,618
Balance, December 31, 2023	$	442,135
Amortization of financing costs		7,431
Accretion and interests		11,649
Conversion to common shares		(461,215)
Balance, September 30, 2024	$	-

During the year ended December 31, 2022, the Company issued a $400,000 principal amount of unsecured convertible debentures (the “Debentures”). The Debentures were issued at original discount of 15% of the principal amount. The original discount amount is being amortized on straight line basis over the term of the Debentures. The Debentures bear interest at a rate of 8% per annum, calculated semi-annually and mature 24 months from the date of issuance. The principal of the Debentures, plus any interest accrual is convertible at the option of the Debentures’ holders into one unit of the Company at the conversion price equal to $0.41 per unit. Each unit consists of one common share and one transferable share purchase warrant, with each warrant being exercisable into one common share at a price of $0.50 for a period of two years from the date of issuance.

On inception, the Company allocated the total proceeds received of $340,551 between liabilities and equity. The equity component of $27,721 was valued using the residual method based on a discount rate of 12%.

During the nine months ended September 30, 2024, the Company has recorded accretion and interest expense in the amount of $11,649 (2023 - $30,584).

On April 5, 2024, the Company entered into a debt settlement agreement with the holders of the Debentures in which the total principal and accrued interest obligations were cancelled in exchange for 1,143,403 of the Company’s common shares and 571,700 warrants to purchase the Company’s common shares at an exercise price of $0.60 per warrant exercised. The Company recognized a loss of convertible debt restructuring of $971,435 as a result of the conversion, which is the difference between the fair value of the common shares and warrants that would have been issued in connection with the original agreement and the fair value of the common shares and warrants that were issued in connection with the debt settlement agreement. Refer to Note 7 for further details of the impacts to share capital.

6. LOAN PAYABLE

As of September 30, 2024, the Company held a shareholders’ loan in the amount of $127,165 (December 31, 2023 - $142,651). During the nine months ended September 30, 2024, the Company made payments totaling $44,215 and drew amounts totaling $28,729 on the shareholders’ loan. The loan is non-interest bearing, unsecured and payable on demand.

7. SHARE CAPITAL AND RESERVES

The Company has authorized an unlimited number of shares with no par value.

Capital Raise

On March 14, 2024, the Company closed a non-brokered private placement of 6,295,500 special warrants of the Company (each, a “March Special Warrant”) at a price of $0.40 per March Special Warrant, for aggregate gross proceeds of $2,518,200 and 975,000 units of the Company (each, a “Unit”) at a price of

7. SHARE CAPITAL AND RESERVES (continued)

$0.40 per Unit, for aggregate gross proceeds of $390,000 (the “March Offering”). A total of $126,123 was allocated to the warrants included in the Units using the relative fair value method.

Each March Special Warrant automatically converts without payment of any additional consideration into one Unit on the date that is the earlier of (i) the third business day after a) a receipt from the applicable securities regulatory authorities for a (final) short form prospectus or b) the date of filing a prospectus supplement (the “Prospectus Supplement”) to a short form base shelf prospectus qualifying the distribution of the Units issuable upon the conversion of the March Special Warrants, and (ii) 4 months and one day after the issue date of the March Special Warrants.

Each Unit is comprised of one common share of the Company (each, a “Share”) and one-half of one share purchase warrant (each whole, a "Warrant") of the Company, with each Warrant exercisable into one additional Share at an exercise price of $0.60 for two (2) years from the date of closing.

On June 18, 2024, the Company filed a Prospectus Supplement. As a result, the March Special Warrants automatically converted into 6,295,500 Shares and 3,147,750 Warrants. The assumptions used in the Black Scholes option pricing model to determine the grant date fair value of the Warrants included in the Unit of $1,624,869 were: (1) expected life of 2.00 years, (2) expected volatility of 286%, (3) dividend yield of 0%, and (4) risk-free rate of 4.00%. A total of $814,368 was allocated to the warrants issued in the Units using the relative fair value method.

In connection with the March Offering, the Company has paid finder’s fees totaling $220,816 and issued an aggregate 552,040 non-transferable broker warrants (the “Broker Warrants”) to arm’s-length parties. Each Broker Warrant entitles the holder to purchase one Share (a “Broker Share”) at an exercise price of $0.60 per Broker Share for a period of two (2) years from the date of closing. The assumptions used in the Black Scholes option pricing model to determine the grant date fair value of the Broker Warrants of $284,963 were: (1) expected life of 2.00 years, (2) expected volatility of 286%, (3) dividend yield of 0%, and (4) risk-free rate of 4.00%.

Legal expenses and other transaction-related costs were $200,147. The Company intends to use the proceeds raised from the March Offering for working capital purposes.

Of the total share issuance cost of $420,963, an amount of $136,136 was allocated to the issuance of warrants included in the Units.

Settlement of Convertible Debentures in Capital Shares

In connection with the debt settlement agreement described in Note 5, the Company issued 1,143,403 of the Company’s common shares with a grant date fair value $754,646 and issued 571,700 warrants to purchase common shares of the Company’s common shares at a price of $0.60 per share. The assumptions used in the Black Scholes option pricing model to determine the grant date fair value of the warrants of $362,007 were: (1) expected life of 2.00 years, (2) expected volatility of 285%, (3) dividend yield of 0%, and (4) risk-free rate of 3.76%.

Settlement of Debt in Capital Shares

On July 5, 2024, the Company entered into Debt Settlement and Release Agreements with three third-party vendors to settle debt resulting from unpaid invoices totaling $650,000. On July 11, 2024, the Company issued a total of 1,160,713 of the Company’s common shares with a fair value of $1,149,406 to settle the debt.

Shares Issued for Services

(Expressed in Canadian Dollars)

7. SHARE CAPITAL AND RESERVES (continued)

On September 18, 2024, the Company issued 39,775 common shares, with a fair value of $30,627, in exchange for services.

Stock Options

The Company adopted the 10% stock option plan (the "Option Plan") on March 11, 2020. The Option Plan provides for the grant of stock options. Stock issued pursuant to awards granted under the 2020 Plan will consist of authorized but unissued common shares. Incentive stock options may be granted to directors, officers, employees and consultants of the Company or a subsidiary of the Company. The Company has reserved 10% of the Company's issued and outstanding common shares. The exercise price shall not be less than the market value of the common shares.

The changes in options during the nine months ended September 30, 2024 and the year ended December 31, 2023 were as follows:

	Nine months ended September 30, 2024		**Year ended December 31, 2023**	
	Number of Options	Weighted Average Exercise Price	Number of Options	Weighted Average Exercise Price
Opening	2,051,500	$0.32	351,500	$7.00
Granted	1,543,000	$0.58	1,700,000	$0.24
Forfeited	(341,500)	$0.71	-	$ -
Ending	3,253,000	$0.40	2,051,500	$1.40
Exercisable	2,326,500	$0.37	779,000	$0.37

The weighted average assumptions that the Company used in the Black Scholes option pricing model to determine the grant date fair value of options granted during the nine months ended September 30, 2024 were: (1) expected life of the options of 4.28 years, (2) expected volatility of 121%, (3) dividend yield of 0%, and (4) risk-free rate of 4.00%.

During the three months ended September 30, 2024, 341,500 options were cancelled due to contract terminations. As a result, in accordance with IFRS 2, *Share-based Payment*, stock-based compensation expenses totaling $499,058 were reversed.

As of September 30, 2024, outstanding incentive stock options were as follows:

Grant Date	Options Outstanding	Options Exercisable	Exercise Price	Expiry Date	Remaining Contractual Life (Years)
January 18, 2021	10,000	10,000	$ 0.32	12/1/2030	6.17
October 3, 2023	300,000	225,000	$ 0.20	10/3/2028	4.01
October 17, 2023	1,400,000	1,200,000	$ 0.25	10/17/2028	4.30
January 8, 2024	25,000	12,500	$ 0.50	1/8/2027	2.27
February 8, 2024	50,000	50,000	$ 0.55	3/1/2029	4.42
February 26, 2024	100,000	100,000	$ 0.55	2/26/2025	0.41
March 1, 2024	870,000	522,000	$ 0.55	3/1/2029	4.42
May 7, 2024	250,000	130,000	$ 0.60	5/7/2029	4.60
May 27, 2024	48,000	32,000	$ 0.51	5/27/2027	2.65
June 18, 2024	50,000	20,000	$ 0.55	6/18/2027	2.72
July 3, 2024	100,000	12,500	$ 0.89	7/3/2026	1.76
July 26, 2024	25,000	5,000	$ 0.85	7/26/2027	2.82
August 6,2024	25,000	7,500	$ 0.73	8/6/2026	1.85
Total	3,253,000	2,326,500	$ 0.37		3.94

(Expressed in Canadian Dollars)

7. SHARE CAPITAL AND RESERVES (continued)

During the three and nine months ended September 30, 2024, the Company recorded stock-based compensation of ($331,901) and $200,788, respectively (three and nine months ended September 30, 2023 - $59,159 and $201,567, respectively) related to share option vesting, net of the reversal of stock-based compensation for cancelled options discussed above.

Special Warrants

	Nine months ended September 30, 2024
	Number of Special Warrants
Opening	-
Issued	6,295,500
Converted	(6,295,500)
Ending	-

On June 21, 2024, the March Special Warrants issued in connection with the March Offering automatically converted into Units without payment of additional consideration, following the successful filing of the Prospectus Supplement to short form base shelf prospectus, qualifying the distribution of the Units issuable upon the conversion of the March Special Warrants. The automatic conversion of the March Special Warrants into Units resulted in the issuance of 6,295,500 Shares and 3,147,750 Warrants.

Warrants

The changes in warrants during the nine months ended September 30, 2024 and the year ended December 31, 2023 were as follows:

	Nine months ended September 30, 2024		Year ended December 31, 2023	
	Number of Warrants	Weighted Average Exercise Price	Number of Warrants	Weighted Average Exercise Price
Opening	175,000	$0.26	-	-
Issued	4,758,990	$0.60	175,000	$0.26
Exercised	(953,690)	$0.57	-	-
Ending	3,980,300	$0.59	175,000	$0.26

As of September 30, 2024, outstanding warrants are as follows:

Number of warrants outstanding	Weighted average exercise price	Expiry Date	Weighted average life remaining (months)
90,000	$ 0.26	September 29, 2025	12.1
3,318,600	$ 0.60	March 13, 2026	17.6
571,700	$ 0.60	April 5, 2026	18.4
3,980,300	**$ 0.59**		**17.6**

Restricted Share Units

The details of the restricted share units ("RSUs") issued are as follows:

(Expressed in Canadian Dollars)

7. SHARE CAPITAL AND RESERVES (continued)

	Nine months ended September 30, 2024	Year ended December 31, 2023
	Number of RSU	Number of RSU
RSUs outstanding, beginning	1,250,000	230,250
Granted	1,210,000	1,250,000
Exercised	(700,000)	-
Expired	-	(230,250)
RSU outstanding, ending	**1,760,000**	**1,250,000**
RSUs vested	**1,070,000**	**233,333**

As of September 30, 2024, outstanding RSUs are as follows:

RSUs Outstanding	Weighted Average Share Price on Grant Date for Outstanding RSUs	RSUs Vested	Weighted Average Share Price on Grant Date for Vested RSUs	Expiry Date	Weighted Average Life Remaining (months)
1,000,000	$ 0.23	800,000	$ 0.23	October 17, 2026	24.9
150,000	$ 0.23	-	$ -	October 17, 2028	49.3
110,000	$ 0.46	80,000	$ 0.46	February 8, 2027	28.7
200,000	$ 0.70	140,000	$ 0.70	April 16, 2027	30.9
300,000	$ 0.77	150,000	$ 0.77	July 26, 2026	22.1
1,760,000	**$ 0.39**	**1,070,000**	**$ 0.37**		**27.4**

During the three and nine months ended September 30, 2024, the Company recorded stock-based compensation of $228,944 and $530,039, respectively (three and nine months ended September 30, 2023 - $nil, respectively) related to RSU vesting.

8. MANAGEMENT OF CAPITAL

The Company considers its capital structure to include the components of shareholders' equity. Management's objective is to ensure that there is sufficient capital to minimize liquidity risk and to continue as a going concern. Although the Company has been successful in the past in obtaining financing, there can be no assurance that the Company will be able to obtain adequate financing in the future, or that the terms of such financings will be favourable. The Company is not subject to any externally imposed capital requirements. There were no changes in the Company's approach to managing capital for the nine months September 30, 2024.

9. FINANCIAL INSTRUMENTS

Classification of financial instruments

Financial instruments included in the consolidated statement of financial position are as follows:

		September 30, 2024 $	December 31, 2023 $
Cash	Fair Value	230,700	715,519
Amounts receivable	Amortized cost	-	17,247
Trade payables	Amortized cost	433,240	892,573
Loan and debentures	Amortized cost	127,165	584,786

9. FINANCIAL INSTRUMENTS (continued)

Fair value

The fair value hierarchy has three levels to classify the inputs to valuation techniques used to measure fair value described as follows:

Level 1 – Unadjusted quoted prices in active markets for identical assets or liabilities;

Level 2 – Inputs other than quoted prices that are observable for the assets or liabilities either directly or indirectly; and

Level 3 – Inputs that are not based on observable market data.

The Company's financial instruments consisted of cash, receivables, trade payables and loan and debentures. The carrying value of receivables, trade payables, and accrued liabilities approximates fair value due to the short-term nature of the instruments. The loan and debentures are booked at amortized costs. Cash and cash equivalents are carried at fair value.

Risk management

The Board of Directors has overall responsibility for the establishment and oversight of the Company's risk management framework. The Company's risk management policies are established to identify and analyze the risks faced by the Company to set appropriate risk limits and controls and to monitor risks and adherence to limits. Risk management policies and systems are reviewed regularly to reflect changes in market conditions and the Company's activities. The Company has exposure to the following risks from its use of financial instruments:

Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. As at September 30, 2024, the Company's working capital was a surplus of $322,871, which was mainly due to cash proceeds from the Offering. As a result, the Company is currently subject to liquidity risk. Historically, the Company's primary source of funding has been the issuance of equity securities for cash, primarily through private placements and loans from related and other parties. The Company's access to financing is always uncertain. There can be no assurance of continued access to significant equity funding.

Interest rate risk

As of September 30, 2024 and December 31, 2023, the Company did not have any significant exposure to the risk of changes in market interest rates as the Company did not have any financial instruments that are exposed to variable interest rates.

Credit risk

Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations.

The potential concentration of credit risk consists mainly of cash and other receivables. The Company limits its counterparty exposures from its cash by only dealing with well-established financial institutions of a high-quality credit standing. The maximum exposure to credit risk is represented by the carrying amount of each financial asset on the statement of financial position.

At the reporting date the majority of the Company's cash resources were deposited with reputable established financial institutions. As a result, management believes the Company is not exposed to significant credit risk due to the credit worthiness of these counterparties.

(Expressed in Canadian Dollars)

9. FINANCIAL INSTRUMENTS (continued)

Foreign currency risk

Foreign currency risk arises from holdings of financial assets and liabilities in currencies other than the functional currency to which they relate. The Company and its subsidiaries have minimal such holdings, consequently foreign currency risk is considered low.

10. SEGMENTED INFORMATION

The Company operates primarily in one business segment, which is the supply of personalized health care information that is relevant and trustworthy to patients. The Company has its head office in Canada and operates mainly in the U.S.A. The Company does not have non-current assets to report on.

11. RELATED PARTY TRANSACTIONS

a) Transactions with key management personnel:

Key management personnel include those persons having authority and responsibility for planning, directing, and controlling the activities of the Company as a whole. The Company has determined that key management personnel consist of executive and non-executive members of the Board of Directors and corporate officers. The aggregate values of transactions relating to key management are as follows:

Nine Months Ended September 30,	**2024**	**2023**
	$	**$**
Salaries, Wages and Consulting fees		
Former Chief Executive Officer & Former Chief Strategy Officer	-	40,431
Chief Executive Officer	180,000	-
Chief Financial Officer	153,772	-
Former Chief Financial Officer & Director	14,700	56,700
Chief Operating Officer	50,000	-
Corporate Secretary	37,074	-
Chief Medical Officer & Director	126,468	300,000

b) Balances due to related parties:

Amounts due to related parties are unsecured, non-interest bearing and have no fixed terms of repayment.

The Company has the following amounts due to related parties:

Due to Related parties	**Nature**	**September 30, 2024**	**December 31, 2023**
		$	$
Former Chief Executive Officer & former Chief Strategy Officer	Consulting fees	-	35,722
Chief Executive Officer	Salary	-	-
Chief Medical Officer & Director	Consulting fees	52,165	67,651
Former Chief Financial Officer & Director	Accounting fee	-	50,635
Chief Financial Officer	Consulting fees	10,146	-

(Expressed in Canadian Dollars)

12. CONTINGENCIES

From time to time, the Company may be involved in claims and litigations as part of its normal course of business. Accruals are made in instances where it is probable that liabilities have been incurred and where such liabilities can be reasonably estimated. Although it is possible that liabilities may be incurred in instances for which no accruals have been made, based on the information currently available, the Company does not believe that any additional provisions are required to be recognized.

13. CORRECTION OF ERROR IN PRIOR PERIOD

During the year ended December 31, 2023, the Company identified that errors were made in the accounting of equity, prepaid expenses and the classification of expenses as of, and for the nine months ended, September 30, 2023, which resulted in an understatement of $1,500,009 in the loss on the settlement of payables for equity, $1,473,089 in share capital, $1,306 in general and administrative expense and an overstatement of $1,306 in prepaid expenses and $26,015 in consulting and professional fees. The Company also identified an errors relating to the incorrect classification of other income as revenues, which resulted in an understatement of $38,136 in other income and an overstatement of $38,136 in revenue and the incorrect classification of research expense as consulting and professional fees, which resulted in an understatement of $300,000 in research expense and an overstatement of $300,000 in consulting and professional fees during the three and nine months ended September 30, 2023.

Summary impact on the statement of loss and comprehensive loss for the three months ended September 30, 2023:

	Three Months Ended September 30, 2023		
	Originally Reported	**Adjustment Increase (Decrease)**	**Restated**
Revenues	$ 38,136	$ (38,136)	$ -
Consulting and professional fees	793,447	(326,920)	466,527
General and administrative	29,096	1,306	30,402
Research	-	300,000	300,000
Loss from operations	(862,639)	(12,522)	(875,161)
Other income	-	38,136	38,136
Loss on settlement of payables for equity	-	(1,500,009)	(1,500,009)
Loss for the period	(836,181)	(1,474,395)	(2,310,576)
Comprehensive loss for the period	**$ (845,120)**	**$ (1,474,395)**	**$ (2,319,515)**

Summary impact on the statement of loss and comprehensive loss for the nine months ended September 30, 2023:

(Expressed in Canadian Dollars)

13. CORRECTION OF ERROR IN PRIOR PERIOD (continued)

	Nine Months Ended September 30, 2023		
	Originally Reported	**Adjustment Increase (Decrease)**	**Restated**
Revenues	$ 38,136	$ (38,136)	$ -
Consulting and professional fees	1,198,396	(326,920)	871,476
General and administrative	109,814	1,306	111,120
Research	-	300,000	300,000
Loss from operations	(1,531,937)	(12,522)	(1,544,459)
Other income	-	38,136	38,136
Loss on settlement of payables for equity	-	(1,500,009)	(1,500,009)
Loss for the period	(1,505,732)	(1,474,395)	(2,980,127)
Comprehensive loss for the period	**$ (1,506,064)**	**$ (1,474,395)**	**$ (2,980,459)**
Loss per share – basic and diluted	$ (0.11)	$ (0.11)	$ (0.22)

Summary impact on the statement of cash flows for the nine months ended September 30, 2023:

	Nine Months Ended September 30, 2023		
	Originally Reported	**Adjustment Increase (Decrease)**	**Restated**
Net income	$ (1,505,732)	$ (1,474,395)	$ (2,980,127)
Shares issued for services	30,422	(26,920)	3,502
Loss on settlement of payables for equity	-	1,500,009	1,500,009
Changes in prepaid expenses	(114,375)	1,306	(113,069)
Cash used in operating activities	**(88,521)**	**-**	**(88,521)**
Cash provided by financing activities	**983,751**	**-**	**983,751**

Summary impact on the equity position for the nine months ended September 30, 2023:

	Nine Months Ended September 30, 2023		
	Originally Reported	**Adjustment Increase (Decrease)**	**Restated**
Shares issued to settle debt for services	$ 1,830,422	$ 1,473,089	$ 3,303,511
Share Capital	15,000	-	15,000
Accumulated deficit	(25,310,034)	(1,474,395)	(26,784,429)
Total deficiency	(665,178)	(1,306)	(666,484)

14. SUBSEQUENT EVENTS

On October 25, 2024, the Company closed a non-brokered private placement of 2,138,766 special warrants of the Company (each, an “October Special Warrant”) at a price of $0.75 per October Special Warrant, for aggregate gross proceeds of $1,604,075 the (“October Offering”).

14. SUBSEQUENT EVENTS (continued)

Each October Special Warrant will automatically convert into one unit of the Company (each a "Unit"). Each Unit consists of one common share of the Company (a "Share") and one-half of one common share purchase warrant (each full warrant, a "Warrant"). Each Warrant entitles the holder thereof to acquire one Share at a price of $1.00 per Share for a period of 24 months following the date of issuance of the Warrants.

Each October Special Warrant will automatically convert, for no additional consideration, into Units on the date (the "Conversion Date") that is the earlier of: (i) the third business day after the date of filing a prospectus supplement to a short form base shelf prospectus (the "Prospectus Supplement") qualifying the distribution of the Shares and Warrants issuable upon the conversion of the October Special Warrants, and (ii) 4 months and one day after the issue date of the October Special Warrants. No October Special Warrants may be exercised by the holder thereof prior to the Conversion Date.

In connection with the October Offering, the Company has paid finder's fees totaling $117,284 and issued an aggregate of 156,378 non-transferable broker warrants (the "October Broker Warrants") to arm's-length parties. Each October Broker Warrant entitles the holder to purchase one Share at an exercise price of $1.00 per Share for a period of two (2) years from the date of closing.

Additionally, the Company offered a sidecar non-brokered private placement of the Units in the province of Quebec (the "October Sidecar Unit Offering") of 466,666 units (the "October Sidecar Units") at the $0.75 per October Sidecar Unit for gross proceeds of $350,000, completed concurrent with the closing of the October Offering. These October Sidecar Units will not be qualified for resale under the Prospectus Supplement and are subject to a four month and one day hold period from the date of issue.

Each October Sidecar Unit consists of one Share of the Company and one-half of one Common Share purchase warrant (each full warrant, an "October Sidecar Warrant") of the Company. Each October Sidecar Warrant entitles the holder thereof to purchase an additional Common Share in the capital of the Company (a "Warrant Share") at an exercise price of $1.00 per Warrant Share, exercisable for a period of 24 months from the date of issuance upon the closing of the October Sidecar Unit Offering. As of the date of this filing, the Company issued 466,666 Shares of the Company and 233,332 October Sidecar Warrants in connection with the October Sidecar Unit Offering.

Subsequent to September 30, 2024, through the date of this filing, the Company has issued the following equity instruments:
Common shares:

- 150,000 common shares in the settlement of RSUs in exchange for services and
- 466,666 common shares in connection with the October Sidecar Unit Offering.

Special Warrants:

- 2,138,766 October Special Warrants in connection with the October Offering

Warrants:

- 156,378 October Broker Warrants, described above and
- 233,332 October Sidecar Warrants in connection with the October Sidecar Unit Offering, described above

In addition, the Company granted 500,000 options to an independent third party in exchange for services.